Emergent BioSolutions lands $24M CYFENDUS order
Emergent BioSolutions Inc. (EBS) reported a new contract modification from the U.S. government to supply its anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted).
Rhea-AI Filing Summary
Emergent BioSolutions Inc. (EBS) reported a new contract modification from the U.S. government to supply its anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted). On August 18, 2026, the company received Modification No. 21 under its long-standing BARDA AV7909 contract, authorizing procurement of additional CYFENDUS doses valued at approximately $24 million.
The BARDA AV7909 contract has been in place since September 30, 2016 and has been modified multiple times to support anthrax preparedness. The press release notes this award supports U.S. anthrax preparedness efforts and follows an earlier 2026 delivery order valued at up to $21.5 million to supply BioThrax® to the U.S. Department of War. CYFENDUS is FDA‑approved as a two‑dose anthrax vaccine for post‑exposure prophylaxis in adults 18–65 years of age when given with recommended antibacterial drugs.
Positive
- $24 million CYFENDUS® contract modification from BARDA under a long-term U.S. government agreement enhances Emergent’s funded role in anthrax preparedness.
- Additional 2026 order up to $21.5 million for BioThrax® from the U.S. Department of War reinforces recurring government demand for Emergent’s anthrax vaccines.
Negative
- None.
Filing Explained
The August 18 modification is executed and values additional CYFENDUS procurement at
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
CYFENDUS contract modification value: $24 million
BioThrax delivery order value: up to $21.5 million
BARDA AV7909 contract effective date: September 30, 2016
+3 more
6 metrics
CYFENDUS contract modification value
$24 million
Value of Modification No. 21 under the BARDA AV7909 contract to procure additional CYFENDUS doses
BioThrax delivery order value
up to $21.5 million
Earlier 2026 delivery order to supply BioThrax to the U.S. Department of War
BARDA AV7909 contract effective date
September 30, 2016
Effective date of Emergent’s development and procurement contract with BARDA
CYFENDUS FDA approval date
July 2023
Month and year CYFENDUS was approved by the U.S. Food and Drug Administration
CYFENDUS indicated age range
18 through 65 years of age
Indication for post-exposure prophylaxis when given with recommended antibacterial drugs
NEJM Evidence volume and issue
5(7)
Volume and issue of NEJM Evidence article on CYFENDUS post-exposure use in Wyoming
Key Terms
Biomedical Advanced Research and Development Authority, post-exposure prophylaxis, Anthrax Vaccine Adsorbed, Adjuvanted, VAERS, +1 more
5 terms
Biomedical Advanced Research and Development Authority regulatory
"from the Biomedical Advanced Research and Development Authority (BARDA), part of the"
A biomedical advanced research and development authority is a government agency that funds and guides the late-stage development and manufacturing of drugs, vaccines, diagnostics and other health technologies, especially those needed for public health emergencies. For investors it matters because its contracts, grants or technical support act like a bridge and safety net—reducing development risk, accelerating timelines and creating a more reliable path to revenue for companies working on critical medical products.
post-exposure prophylaxis medical
"as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals"
A short course of medication or treatment given immediately after someone may have been exposed to an infectious agent to stop the infection from taking hold. Like applying a firewall after a suspected hacking attempt, it’s intended to prevent a small risk from becoming a full-blown problem. For investors, post-exposure prophylaxis matters because demand can spike suddenly after exposure events, regulatory approvals and efficacy data drive sales and valuation, and timely access or shortages affect market opportunity and reputational risk for healthcare providers and drug makers.
Anthrax Vaccine Adsorbed, Adjuvanted medical
"to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness"
VAERS regulatory
"or VAERS at 1-800-822-7967 or www.vaers.hhs.gov."
NEJM Evidence medical
"A recent NEJM Evidence study by Tillman et al. examines the use"
FAQ
What contract did Emergent BioSolutions (EBS) announce in this 8-K?
Emergent announced a BARDA contract modification, Modification No. 21 under the AV7909 contract, to procure additional doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) valued at approximately $24 million for U.S. anthrax preparedness efforts.
How much is the new CYFENDUS contract modification worth for EBS?
The newly executed U.S. government contract modification for CYFENDUS® is valued at approximately $24 million, covering additional doses under Emergent’s existing BARDA AV7909 development and procurement contract that became effective on September 30, 2016.
What is the BARDA AV7909 contract mentioned by Emergent BioSolutions (EBS)?
The BARDA AV7909 contract is Emergent’s development and procurement agreement with BARDA, effective September 30, 2016, supporting CYFENDUS® for anthrax preparedness. It has been modified multiple times, including Modification No. 21 for about $24 million in additional doses.
For whom is CYFENDUS approved, according to Emergent BioSolutions (EBS)?
CYFENDUS® is FDA‑approved as a two-dose anthrax vaccine for post‑exposure prophylaxis after suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age, when administered with recommended antibacterial drugs.
What key safety considerations for CYFENDUS does EBS highlight?
Emergent notes CYFENDUS® is contraindicated in individuals with severe allergic reactions to CYFENDUS®, BioThrax®, or components, and warns it can cause fetal harm when administered during pregnancy. Common adverse reactions include injection-site tenderness, pain, and systemic symptoms such as muscle aches, tiredness, and headache.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 18, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||||||||||||
| of incorporation) | Identification No.) | |||||||||||||
(Address of principal executive offices, including zip code)
(240 ) 631-3200
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On August 18, 2026, Emergent BioSolutions Inc. (“Emergent”) received a contract modification (“Modification No. 21”) of the BARDA AV7909 Contract (as defined below) from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) (previously known as “AV7909”) valued at $24 million.
This modification relates to Emergent’s AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority (“BARDA”), which became effective on September 30, 2016 (the “BARDA AV7909 Contract”) and has been modified from time to time. The preceding description of Modification No. 21 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification No. 21. Modification No. 21, with relevant redactions to protect confidential and sensitive information, is filed herewith as Exhibit 10.1 and is incorporated herein by reference. The BARDA AV7909 Contract is filed as a material agreement of Emergent as Exhibit 10.51 with Emergent’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
On September 1, 2026, Emergent issued a press release announcing the contract modification. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 10.1 | Modification No. 21, effective August 18, 2026 to the BARDA AV7909 Contract | |||||||
| 99.1 | Press release issued by Emergent BioSolutions Inc. on September 1, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EMERGENT BIOSOLUTIONS INC. | ||||||||
| Dated: September 1, 2026 | By: | /s/ RICHARD S. LINDAHL | ||||||
| Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer | ||||||||
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
GAITHERSBURG, Md., September 1, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts. Anthrax remains a significant global biological threat due to its potential use in a bioterrorism event and its implications for public health and national security.
“This newly executed CYFENDUS® contract modification with the U.S. government highlights the continued importance of maintaining readiness against anthrax threats,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “Emergent remains committed to ensuring access to CYFENDUS® and strengthening preparedness through reliable domestic manufacturing and supply.”
CYFENDUS® was approved by the U.S. Food and Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age when given with recommended antibacterial drugs. A recent NEJM Evidence study by Tillman et al. examines the use of the CYFENDUS® vaccine for post-exposure prophylaxis following anthrax exposures in Wyoming, further reinforcing the importance of maintaining preparedness capabilities and access to effective medical countermeasures against this high-consequence biological threat.1
This award builds on Emergent’s work with the U.S. government to support anthrax preparedness. Earlier this year, Emergent announced a delivery order valued at up to $21.5 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War.
This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201600030C.
About CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Indication
CYFENDUS® (Anthrax Vaccine Absorbed, Adjuvanted) is a vaccine indicated for post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when given with recommended antibacterial drugs. The efficacy of CYFENDUS® vaccine for post-exposure prophylaxis (PEP) is based solely on studies in animal models of inhalational anthrax.
Important Safety Information
Contraindication: Do not administer CYFENDUS® to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) following a previous dose of CYFENDUS®, BioThrax® (a licensed anthrax vaccine with the same active ingredient as CYFENDUS®) or any component of the vaccine.
Warnings and Precautions: Management of Acute Allergic Reactions: Appropriate medical treatment must be available to manage possible anaphylactic reactions following administration of CYFENDUS®. Pregnancy: CYFENDUS® can cause fetal harm when administered to a pregnant
individual. In an observational study, there were more birth defects in infants born to individuals vaccinated with BioThrax® (a licensed anthrax vaccine with the same active ingredient as CYFENDUS®) in the first trimester compared to infants born to individuals vaccinated post pregnancy or individuals never vaccinated with BioThrax®.
Adverse Reactions: The most common (≥10%) injection-site adverse reactions reported were tenderness, pain, arm motion limitation, warmth, induration, itching, swelling, and erythema/redness. The most common systemic adverse reactions were muscle aches, tiredness, and headache.
To report Suspected Adverse Reactions, contact Emergent BioSolutions at 1-800-768-2304 or medicalinformation@ebsi.com; or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.
Please see the Prescribing Information for CYFENDUS® for full safety information.
About BioThrax® (Anthrax Vaccine Adsorbed) BioThrax® vaccine is indicated for the active immunization for the prevention of disease caused by Bacillus anthracis in persons 18 through 65 years of age. BioThrax® is approved for (1) pre-exposure prophylaxis of disease in persons at high risk of exposure; and (2) post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs. The efficacy of BioThrax® for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax.
Select Important Safety Information
Contraindication: Severe allergic reaction (e.g., anaphylaxis) after a previous dose of BioThrax® or a component of the vaccine. Warnings and Precautions: Latex: The stopper of the vial contains natural rubber latex and may cause allergic reactions in latex sensitive individuals. Pregnancy: Avoid use in pregnancy unless the potential benefit outweighs the potential risk to the fetus. Adverse Reactions: The most common (>10%) local (injection-site) adverse reactions observed in clinical studies were tenderness, pain, erythema, edema, and arm motion limitation. The most common (≥5%) systemic adverse reactions were muscle aches, fatigue, and headache.
Please see the full Prescribing Information for BioThrax® for additional safety information.
About Emergent BioSolutions At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the expected timing for delivery of the CYFENDUS® vaccine and Emergent’s ability to increase inventories of CYFENDUS® vaccine to meet requested levels within specified time frames, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot
guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
1Tillman, C., Waranius, B. N., Van Houten, C., & Harrist, A. (2026). Cyfendus for Postexposure Prophylaxis after Inhalation Anthrax Exposures in Wyoming. NEJM Evidence, 5(7), EVIDpha2600122. doi.org.